Toxicity of an Fc-engineered anti-CD40 antibody is abrogated by intratumoral injection and results in durable antitumor immunity
Crossref DOI link: https://doi.org/10.1073/pnas.1810566115
Published Online: 2018-10-08
Published Print: 2018-10-23
Update policy: https://doi.org/10.1073/pnas.cm10313
Knorr, David A.
Dahan, Rony
Ravetch, Jeffrey V. http://orcid.org/0000-0003-2024-9041
Funding for this research was provided by:
NCI (R35CA196620 0)
NIH (P01CA190174)
V Foundation for Cancer Research (T2017-002)
Robertson Therapeutic Development Fund (N/A)
Version of Record valid from 2019-04-08
Publication History
Published: 2018-10-08